Columns & Departments
Drug & Device News
Bellwether Trial Opening in Vaginal Mesh MDL <br>NuvaRing Settlement in the Works
Features
New Jersey Case Study
There has been a lack of consistency in malpractice cases where the plaintiff has settled with one or more defendants, and then goes to trial against other defendants. However, a recently published New Jersey Law Division case has brought a measure of consistency to this issue.
Features
New Jersey Manufacturers and Punitive Damages
As discussed in Part One of this article, New Jersey's Products Liability Act (Defective Product) (PLA), N.J. Stat. ' 2A:58C-5 (c) (2013), prevents injured plaintiffs seeking compensation from drug and device manufacturers from being awarded punitive damages. The statute, which in an earlier form was enacted in 2008, provides, in pertinent part:
Columns & Departments
Drug & Device News
Discussion of news and litigation.
Columns & Departments
Med Mal News
Recent news items of importance.
Features
Judicial Scrutiny of 'Other Insurance' Clauses
Conclusion of a discussion of the ways in which different jurisdictions treat "excess insurance" clauses ' those that describe an insurer's obligation when more than one insurance policy provides coverage to the same insured for the same loss.
Features
OCD: Beware Misdiagnosis
In the case of the diagnosis of "obsessive compulsive disorder" (OCD), a misdiagnosis may send the patient down the wrong treatment path entirely.
Features
New Jersey Manufacturers and Punitive Damages
The state of New Jersey is home to the headquarters of 17 of the top 20 drug-producing companies in the world. These include pharmaceuticals producers Wyeth, Merck and Co. and Johnson & Johnson.
Columns & Departments
Verdicts
Rulings of interest and importance to med mal attorneys.
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- Protecting Innovation in the Cyber World from Patent TrollsWith trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.Read More ›
- Meet the Lawyer Working on Inclusion Rider LanguageAt the Oscars in March, Best Actress winner Frances McDormand made “inclusion rider” go viral. But Kalpana Kotagal, a partner at Cohen Milstein Sellers & Toll had already worked for months to write the language for such provisions. Kotagal was developing legal language for contract provisions that Hollywood's elite could use to require studios and other partners to employ diverse workers on set.Read More ›
- From the PTO to the FDA: What to Consider When Branding Clinical TrialsThe legal implications of branding generally arise initially for companies during the process of selecting a company name and any initial product or service names. For drug development companies, however, careful consideration should also be paid to the implications of branding a clinical trial.Read More ›
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›